eFFECTOR Therapeutics, Inc.
NASDAQ:EFTR
0.04 (USD) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0.162 | 0 | 0 | 0 | 0.675 | 0.867 | 2.011 | 0 | 1.43 | 0.427 | 0.692 | 0 | 0.042 | 0.574 | 15.055 | 26.329 |
| Cost of Revenue
| 0.028 | 0.03 | 0.026 | 0.027 | 0.028 | 0.027 | 0.018 | 0.003 | 0.005 | 0.004 | 0.006 | 4.072 | 0.007 | 4.601 | 6.78 | 4.826 | 5.625 |
| Gross Profit
| -0.028 | 0.132 | -0.026 | -0.027 | -0.028 | 0.648 | 0.849 | 2.008 | -0.005 | 1.426 | 0.421 | -3.38 | -0.007 | -4.559 | -6.206 | 10.229 | 20.704 |
| Gross Profit Ratio
| 0 | 0.815 | 0 | 0 | 0 | 0.96 | 0.979 | 0.999 | 0 | 0.997 | 0.986 | -4.884 | 0 | -108.548 | -10.812 | 0.679 | 0.786 |
| Reseach & Development Expenses
| 5.278 | 6.043 | 5.355 | 4.881 | 6.609 | 6.649 | 6.632 | 6.919 | 3.112 | 6.394 | 5.022 | 4.072 | 4.468 | 4.601 | 6.78 | 4.826 | 5.625 |
| General & Administrative Expenses
| 3.09 | 2.524 | 2.5 | 2.974 | 2.927 | 2.748 | 3.486 | 2.973 | 3.436 | 6.32 | 4.119 | 1.664 | 1.269 | 1.06 | 1.063 | 1.125 | 1.101 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 3.09 | 2.524 | 2.5 | 2.974 | 2.927 | 2.748 | 3.486 | 2.973 | 3.436 | 6.32 | 4.119 | 1.664 | 1.269 | 1.06 | 1.063 | 1.125 | 1.101 |
| Other Expenses
| -0.012 | 0.003 | 0 | -0.014 | -0.478 | -0.674 | -0.867 | -2.011 | -0.686 | -0.311 | 0.29 | -0.025 | -0.048 | 0.077 | 0.004 | 0 | 0 |
| Operating Expenses
| 8.368 | 8.567 | 7.855 | 7.855 | 9.536 | 8.723 | 9.251 | 7.881 | 6.548 | 12.403 | 8.714 | 5.044 | 5.737 | 5.661 | 7.843 | 1.186 | 1.112 |
| Operating Income
| -8.396 | -8.597 | -8.303 | -7.855 | -9.325 | -8.723 | -9.251 | -7.881 | -6.548 | 20.029 | -8.714 | -5.044 | -5.737 | -5.619 | -7.269 | 9.104 | 19.603 |
| Operating Income Ratio
| 0 | -53.068 | 0 | 0 | 0 | -12.923 | -10.67 | -3.919 | 0 | 14.006 | -20.407 | -7.289 | 0 | -133.786 | -12.664 | 0.605 | 0.745 |
| Total Other Income Expenses Net
| -0.438 | -0.532 | 0.006 | -0.014 | -0.689 | -0.538 | -0.308 | 0.966 | 9.617 | -0.98 | 18.08 | -0.025 | -0.54 | 0.077 | 0.004 | -0.385 | -0.302 |
| Income Before Tax
| -8.834 | -9.129 | -8.303 | -8.364 | -10.014 | -9.26 | -9.559 | -6.915 | 3.069 | 19.049 | 8.879 | -5.548 | -6.582 | -5.854 | -7.604 | 8.719 | 19.301 |
| Income Before Tax Ratio
| 0 | -56.352 | 0 | 0 | 0 | -13.719 | -11.025 | -3.439 | 0 | 13.321 | 20.794 | -8.017 | 0 | -139.381 | -13.247 | 0.579 | 0.733 |
| Income Tax Expense
| -0.015 | -0.688 | -0.02 | 0.708 | -0.253 | -0.028 | 0.171 | 0.187 | -0.662 | -32.436 | 0.778 | 0.449 | 0.258 | -5.066 | 0.005 | 0.126 | 0.22 |
| Net Income
| -8.834 | -9.129 | -8.303 | -8.364 | -10.014 | -9.26 | -9.559 | -6.915 | 3.069 | 19.049 | 8.879 | -5.548 | -6.582 | -0.397 | -7.609 | 7.436 | 0.736 |
| Net Income Ratio
| 0 | -56.352 | 0 | 0 | 0 | -13.719 | -11.025 | -3.439 | 0 | 13.321 | 20.794 | -8.017 | 0 | -9.452 | -13.256 | 0.494 | 0.028 |
| EPS
| -2.16 | -3.42 | -3.36 | -4.37 | -5.96 | -5.57 | -5.8 | -4.2 | 1.77 | 11.79 | 5.5 | -6.15 | -11 | -0.66 | -12.71 | 134.79 | 13.342 |
| EPS Diluted
| -2.16 | -3.42 | -3.36 | -4.37 | -5.96 | -5.57 | -5.8 | -4.2 | 1.77 | 11.79 | 5.5 | -6.15 | -11 | -0.66 | -12.71 | 134.79 | 13.342 |
| EBITDA
| -8.368 | -8.567 | -8.303 | -7.615 | -9.536 | -8.723 | -9.053 | -7.691 | -7.205 | -12.403 | -8.417 | -5.068 | -5.777 | -5.507 | -7.262 | 9.145 | 19.649 |
| EBITDA Ratio
| 0 | -52.883 | 0 | 0 | 0 | -12.923 | -10.442 | -3.824 | 0 | -8.673 | -19.712 | -7.324 | 0 | -131.119 | -12.652 | 0.607 | 0.746 |